Random forest algorithm identifies miRNA signatures for breast cancer detection and classification from patient urine samples.

IF 4.3 2区 医学 Q2 ONCOLOGY
Therapeutic Advances in Medical Oncology Pub Date : 2024-12-13 eCollection Date: 2024-01-01 DOI:10.1177/17588359241299563
Jochen Maurer, Matthias Rübner, Chao-Chung Kuo, Birgit Klein, Julia Franzen, Julia Wittenborn, Tomas Kupec, Laila Najjari, Peter Fasching, Elmar Stickeler
{"title":"Random forest algorithm identifies miRNA signatures for breast cancer detection and classification from patient urine samples.","authors":"Jochen Maurer, Matthias Rübner, Chao-Chung Kuo, Birgit Klein, Julia Franzen, Julia Wittenborn, Tomas Kupec, Laila Najjari, Peter Fasching, Elmar Stickeler","doi":"10.1177/17588359241299563","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Breast cancer is the most common cancer in women, with one in eight women suffering from this disease in her lifetime. The implementation of centrally organized mammography screening for women between 50 and 69 years of age was a major step in the direction of early detection. However, the participation rate reaches approximately 50% of the eligible women, one reason being the painful compression of the breast, cited as a major issue for not participating in this very important program. Therefore, focusing current research on less painful and less invasive techniques for the detection of breast cancer is highly clinically relevant. Liquid biopsies offer this option by detection of distinct molecules such as microRNAs (miRNAs) or circulating tumor DNA (ctDNA) or disseminated tumor cells.</p><p><strong>Design and methods: </strong>Here, we present the first proof-of-concept approach for sequencing miRNAs in female urine to detect breast cancer and, subsequently, intrinsic subtype-specific miRNA patterns and implement in this regard a novel random forest algorithm. To this end, we performed miRNA sequencing on 82 urine samples, 32 samples from breast cancer patients (9× luminal A, 8× luminal B, 9× triple-negative, and 6× HER2) and 50 healthy control samples.</p><p><strong>Results and conclusion: </strong>Using a random forest algorithm, we identified a signature of 275 miRNAs that allows the detection of invasive breast cancer in urine. Furthermore, we identified distinct miRNA expression patterns for the major intrinsic subtypes of breast cancer, specifically luminal A, luminal B, HER2-enriched, and triple-negative breast cancer. This experimental approach specifically validates miRNA sequencing as a technique for breast cancer detection in urine samples and opens the door to a new, easy, and painless procedure for different breast cancer-related medical procedures such as screening but also treatment monitoring.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241299563"},"PeriodicalIF":4.3000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645719/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241299563","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: Breast cancer is the most common cancer in women, with one in eight women suffering from this disease in her lifetime. The implementation of centrally organized mammography screening for women between 50 and 69 years of age was a major step in the direction of early detection. However, the participation rate reaches approximately 50% of the eligible women, one reason being the painful compression of the breast, cited as a major issue for not participating in this very important program. Therefore, focusing current research on less painful and less invasive techniques for the detection of breast cancer is highly clinically relevant. Liquid biopsies offer this option by detection of distinct molecules such as microRNAs (miRNAs) or circulating tumor DNA (ctDNA) or disseminated tumor cells.

Design and methods: Here, we present the first proof-of-concept approach for sequencing miRNAs in female urine to detect breast cancer and, subsequently, intrinsic subtype-specific miRNA patterns and implement in this regard a novel random forest algorithm. To this end, we performed miRNA sequencing on 82 urine samples, 32 samples from breast cancer patients (9× luminal A, 8× luminal B, 9× triple-negative, and 6× HER2) and 50 healthy control samples.

Results and conclusion: Using a random forest algorithm, we identified a signature of 275 miRNAs that allows the detection of invasive breast cancer in urine. Furthermore, we identified distinct miRNA expression patterns for the major intrinsic subtypes of breast cancer, specifically luminal A, luminal B, HER2-enriched, and triple-negative breast cancer. This experimental approach specifically validates miRNA sequencing as a technique for breast cancer detection in urine samples and opens the door to a new, easy, and painless procedure for different breast cancer-related medical procedures such as screening but also treatment monitoring.

随机森林算法从患者尿液样本中识别乳腺癌检测和分类的miRNA特征。
背景和目的:乳腺癌是妇女中最常见的癌症,每8名妇女中就有1人患有这种疾病。对50至69岁的妇女实施集中组织的乳房x光检查是朝着早期发现方向迈出的重要一步。然而,大约50%的符合条件的妇女参加了这个项目,其中一个原因是乳房压迫疼痛,这是没有参加这个非常重要的项目的主要问题。因此,将目前的研究重点放在疼痛更少、侵入性更小的乳腺癌检测技术上,具有很高的临床意义。液体活检通过检测不同的分子,如microrna (miRNAs)或循环肿瘤DNA (ctDNA)或播散性肿瘤细胞,提供了这种选择。设计和方法:在这里,我们提出了第一个概念验证方法,对女性尿液中的miRNA进行测序,以检测乳腺癌,随后,内在的亚型特异性miRNA模式,并在这方面实现了一种新的随机森林算法。为此,我们对82份尿液样本、32份乳腺癌患者样本(9份luminal A、8份luminal B、9份三阴性和6份HER2)和50份健康对照样本进行了miRNA测序。结果和结论:使用随机森林算法,我们确定了275个mirna的签名,可以在尿液中检测浸润性乳腺癌。此外,我们确定了乳腺癌主要内在亚型的不同miRNA表达模式,特别是管腔A,管腔B, her2富集和三阴性乳腺癌。这种实验方法特别验证了miRNA测序作为尿液样本中乳腺癌检测的技术,并为不同的乳腺癌相关医疗程序(如筛查和治疗监测)打开了一扇新的、简单的、无痛的程序之门。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.20
自引率
2.00%
发文量
160
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信